Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

218 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Considerations on the use of urine markers in the management of patients with high-grade non-muscle-invasive bladder cancer.
Kamat AM, Vlahou A, Taylor JA, Hudson ML, Pesch B, Ingersoll MA, Todenhöfer T, van Rhijn B, Kassouf W, Barton Grossman H, Behrens T, Chandra A, Goebell PJ, Palou J, Sanchez-Carbayo M, Schmitz-Dräger BJ. Kamat AM, et al. Among authors: pesch b. Urol Oncol. 2014 Oct;32(7):1069-77. doi: 10.1016/j.urolonc.2014.06.017. Epub 2014 Oct 11. Urol Oncol. 2014. PMID: 25306288 Review.
Considerations on the use of urine markers in the management of patients with low-/intermediate-risk non-muscle invasive bladder cancer.
Schmitz-Dräger BJ, Todenhöfer T, van Rhijn B, Pesch B, Hudson MA, Chandra A, Ingersoll MA, Kassouf W, Palou J, Taylor J, Vlahou A, Behrens T, Critelli R, Grossman HB, Sanchez-Carbayo M, Kamat A. Schmitz-Dräger BJ, et al. Among authors: pesch b. Urol Oncol. 2014 Oct;32(7):1061-8. doi: 10.1016/j.urolonc.2013.10.010. Epub 2014 Jan 9. Urol Oncol. 2014. PMID: 24411790 Review.
Toward noninvasive follow-up of low-risk bladder cancer - Rationale and concept of the UroFollow trial.
Benderska-Söder N, Hovanec J, Pesch B, Goebell PJ, Roghmann F, Noldus J, Rabinovich J, Wichert K, Gleichenhagen J, Käfferlein HU, Köhler CU, Johnen G, Kernig K, Hakenberg O, Jahn D, Todenhöfer T, Stenzl A, Gleissner J, Gerwert K, El-Mashtoly S, Behrens T, Brüning T, Schmitz-Dräger BJ. Benderska-Söder N, et al. Among authors: pesch b. Urol Oncol. 2020 Dec;38(12):886-895. doi: 10.1016/j.urolonc.2020.01.006. Epub 2020 Mar 18. Urol Oncol. 2020. PMID: 32199755 Review.
Prospective evaluation of fluorescence-in situ-hybridization to detect bladder cancer: results from the UroScreen-Study.
Banek S, Schwentner C, Täger D, Pesch B, Nasterlack M, Leng G, Gawrych K, Bonberg N, Johnen G, Kluckert M, Gakis G, Todenhöfer T, Hennenlotter J, Brüning T, Stenzl A; UroScreen Study Group. Banek S, et al. Among authors: pesch b. Urol Oncol. 2013 Nov;31(8):1656-62. doi: 10.1016/j.urolonc.2012.04.015. Epub 2012 May 22. Urol Oncol. 2013. PMID: 22621963
Urinary bladder cancer risk factors in Egypt.
Behrens T, Pesch B, Brüning T. Behrens T, et al. Among authors: pesch b. Cancer Epidemiol Biomarkers Prev. 2012 Apr;21(4):693; author reply 694-5. doi: 10.1158/1055-9965.EPI-12-0003. Epub 2012 Feb 10. Cancer Epidemiol Biomarkers Prev. 2012. PMID: 22328351 No abstract available.
Chromosomal instability and bladder cancer: the UroVysion(TM) test in the UroScreen study.
Bonberg N, Taeger D, Gawrych K, Johnen G, Banek S, Schwentner C, Sievert KD, Wellhäußer H, Kluckert M, Leng G, Nasterlack M, Stenzl A, Behrens T, Brüning T, Pesch B; UroScreen Study Group. Bonberg N, et al. Among authors: pesch b. BJU Int. 2013 Aug;112(4):E372-82. doi: 10.1111/j.1464-410X.2012.11666.x. Epub 2013 Jan 25. BJU Int. 2013. PMID: 23350736
218 results